FIFrank F. Ing

Frank F. Ing

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Frank F. Ing has a total of 12 co-authors. Here are the top co-authors by number of shared publications:

  • Frances C. Travelli

    Department of Pediatrics,Keck School of Medicine,Division of Cardiology,Children's Hospital Los Angeles,University of Southern California,Los Angeles,California,United States of America

    2 shared publications
  • Asra Khan

    Lillie Frank Abercrombie Section of Pediatric Cardiology, Texas Children's Hospital, Baylor College of Medicine Houston Texas

    1 shared publication
  • Cheryl M. Takao

    Children's Hospital Los Angeles, Division of Cardiology, Los Angeles, CA, 90027

    1 shared publication
  • Cheryl Takao

    Department of Pediatrics,Keck School of Medicine,Division of Cardiology,Children's Hospital Los Angeles,University of Southern California,Los Angeles,California,United States of America

    1 shared publication
  • Cynthia S. Herrington

    Division of Cardiology, Department of Cardiothoracic Surgery, Children's Hospital Los Angeles, University of Southern California, Los Angeles, Calif

    1 shared publication
  • Daisuke Kobayashi

    Division of Cardiology, Children's Hospital of Michigan, Wayne State University Detroit Michigan

    1 shared publication

Latest Publications

  • The Valeo stent: a pre-mounted, open-cell, large stent for use in small children with CHD

    by Frances C. Travelli, Patrick M. Sullivan, Cheryl Takao, Frank F. Ing

    Objectives: The aim of the present study was to determine the outcomes of using the Valeo stent (Bard Peripheral Vascular, Tempe, Arizona, United States of America) in small children with CHD.Background: Stenting vascular stenoses is safe and effective in adults and older children with CHD but is limited in smaller children. The design of the Valeo stent addresses these limitations but has not been extensively described.Methods: Bench testing was conducted to determine the maximum diameter of the stent, foreshortening, and side-cell diameter. A retrospective analysis of Valeo stents implanted between October, 2012 and October, 2014 was performed. Patient profile, pre-implant/post-implant catheterization data, and stent geometry were reviewed.Results: Bench testing: medium and large Valeo stents can be dilated up to 13 mm and 20 mm diameters, respectively. Side-cells are dilatable up to 12 mm. Valeo stents are of low profile – delivered through 6- or 7-Fr sheaths – and show minimal foreshortening. Retrospective analysis: a total of 81 stents were implanted in 61 patients with CHD. The median weight was 15.3 kg, and the median age was 58.9 months. Stents were implanted in the pulmonary artery, systemic vein, aorta, and pulmonary vein. Overall, mean vessel diameters increased from 4.1 to 7.7 mm (121.7%). There was effective mean gradient reduction: 3.7–0.5 mmHg (63%) in the venous systems, 28.2–12.5 mmHg (63.7%) in the pulmonary arteries, and 17.4–4 mmHg (77.1%) in the aorta. The mean stent foreshortening was 2.5%, and the mean recoil was 5.9%. Side-cells that crossed other vessels were dilated in four cases, and stents were re-mounted onto different-sized balloons in seven cases.Conclusions: The features of the Valeo stent, such as low profile, large maximum diameter, open-cell design, minimal foreshortening, and recoil, make it suitable for treating vascular stenoses in small children with CHD.


  • Pulmonary artery stents in the recent era

    by Frank F. Ing, Asra Khan, Daisuke Kobayashi, Donald J. Hagler, Thomas J. Forbes

    Background: Long‐term follow‐up after stent dilation of native and acquired pulmonary artery stenosis is scarce in the pediatric population. Most cohorts include a myriad of anatomies and associated conditions.Method: In order to establish objective performance criteria, we performed a retrospective review of all patients who underwent unilateral pulmonary artery stenting in biventricular physiology at three centers from June 2006 to June 2011.Results: Fifty‐eight patients received 60 stents with Palmaz Genesis stent used most commonly (78%). Average age at implantation was 10.4 ± 10.3 years and weight 31.6 ± 21.8 kg. The immediate success rate was 98%, with improvement in minimal diameter from 5.1 ± 2 cm to 10.6 ± 3 cm (P < 0.01). There were 10 complications (7 major and 3 minor) and no acute mortality. One‐year follow‐up studies were available in 48 patients (83%), including echocardiogram (60%), catheterization (28%), MRI (29%), and lung perfusion (31%). Follow‐up echocardiogram showed mild increase in stent gradient, from 5.7 ± 6.7 mm Hg post‐procedure to 17.1 ± 11.7 mm Hg. Follow‐up catheterization showed no significant change in minimal stent diameter (8.8 ± 2.6 to 7.8 ± 2.3 mm), gradient (7.7 ± 8.4 to 12.6 ± 12.2 mm Hg), or right ventricular pressures (43.7 ± 9 to 47.7 ± 10.5 mm Hg). Nine patients (16%) underwent scheduled stent redilation over a period of 12 days to 25 months.Conclusion: In conclusion, stent implantation shows excellent immediate and 1‐year follow‐up results with maintenance of improved caliber of the stented vessel and lowered right ventricular systolic pressures.


  • Impact of stent implantation on pulmonary artery growth

    by Cheryl M. Takao, Howaida El Said, Dana Connolly, Rabih K. Hamzeh, Frank F. Ing

    Background: Goals of stent implantation (SI) in children with pulmonary artery (PA) stenosis are to relieve obstruction and improve flow to the distal vasculature. We evaluated stent impact on distal PA growth.Methods: We compared data of children who underwent unilateral SI using the nonstenotic contralateral PA (CPA) as a control (1998–2005; f/u data through 2009). Main/lobar diameters measured at initial and f/u catheterizations were analyzed.Results: For single ventricle (SV) patients (N = 18), the stented PA diameter (SPA D) increased 118%. At initial f/u catheterization (14 ± 9.6 months), both upper lobe (UL) and lower lobe (LL) growth of SPA was comparable to those of the CPA (UL:7% vs. 7%; P = 0.97); (LL:5% vs. 10%; P = 0.33). Subsequent f/u in 11/18 patients (mean 26 ± 20 months) revealed similar results: both UL and LL growth of SPA were comparable to those of the CPA (UL:51% vs. 27%; P = 0.3); (LL:18% vs. 21%; P = 0.62). For two‐ventricle (2V) patients (N = 21), the SPAD increased 100%. At f/u, UL, and LL growth on SPA was similar to those of the CPA (UL: 32% vs. 21%; P = 0.37); (LL: 17% vs. 18%; P = 0.88). Subsequent f/u in 10/21 patients (mean 34 ± 14 months) showed UL growth of SPA was significantly greater than that of the CPA (44% vs. 21%; P = 0.05). LL growth of SPA was similar to that of the CPA (19% vs. 14%; P = 0.56).Conclusion: SI for PA stenosis is effective in promoting normal lobar growth in SV and 2V patients. Greater lobar growth was seen in 2V compared to SV pts at first f/u. Early, aggressive PA stenting is beneficial in promoting lobar branch growth.